Treatment adherence and mental health in people with cystic fibrosis and advanced lung disease treated with elexacaftor/tezacaftor/ivacaftor.
A cystic fibrosis therapy delivered sustained lung benefits and improved quality of life, though some patients experienced manageable neuropsychological side effects.
This PubMed-indexed study examined iNTRODUCTION: Advanced lung disease (ALD) is a leading cause of mortality in cystic fibrosis (CF). The abstract reports eTI provided sustained pulmonary and HRQoL benefits, although persistent neuropsychological side-effects occurred in a subset of participants and were associated with anxiety.
What the study was
- Study design
- Observational/Cohort Study
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Pulmonology
Why it surfaced
Conservative triage based on the PubMed abstract: observational/cohort study with direct watchlist relevance; score reflects metadata and abstract-level evidence only.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.